Shanghai Allist Pharmaceuticals Co.,Ltd. recently announced its first half 2025 financial results, demonstrating robust growth across key metrics. The company recorded operating revenue of 23.74 billion yuan, representing a 50.57% year-over-year increase. Net profit attributable to shareholders reached 10.51 billion yuan, up 60.22% compared to the same period last year. Operating cash flow generated during the reporting period totaled 10.93 billion yuan, marking a 49.62% year-over-year rise.
During the first half of 2025, Shanghai Allist Pharmaceuticals' commercialized products - furmonertinib, goletregace, and pralsetinib - all achieved significant progress, showcasing the company's development potential across different therapeutic areas.
Furmonertinib, serving as the company's flagship product, generated sales revenue of 23.6 billion yuan in the first half, representing nearly 51% growth year-over-year and accounting for 99.4% of total revenue. The drug has been included in multiple authoritative treatment guidelines, including the CSCO Non-Small Cell Lung Cancer Guidelines (2022 Edition), further enhancing its market recognition. Additionally, furmonertinib's international commercialization is actively advancing, with the ArriVent partnership providing support for overseas expansion.
Goletregace received approval from China's National Medical Products Administration in May 2025 for treating adult patients with KRAS G12C mutation-positive advanced non-small cell lung cancer who have received at least one prior systemic therapy. The commercialization process has shown a promising start. Simultaneously, Phase III clinical trials combining goletregace with SHP2 inhibitor AST24082 for first-line NSCLC treatment with KRAS G12C mutations, as well as multi-tumor studies for pancreatic and other solid tumors, are progressing smoothly.
Pralsetinib's domestic commercialization is underway, with the marketing application for transferring production from overseas to domestic facilities already approved by China's National Medical Products Administration. Starting in 2026, complete localized production from active pharmaceutical ingredients to finished products is expected, ensuring stable supply, reducing production costs, and preparing for potential inclusion in national health insurance coverage.
Regarding production capacity upgrades and international cooperation, Shanghai Allist Pharmaceuticals has demonstrated excellent performance. The company's Jiangsu facility has received approval to officially launch a new production line capable of producing 150 million tablets of furmonertinib mesylate solid dosage forms annually. Combined with existing production capacity, the furmonertinib mesylate tablet production facility now has an annual capacity of 200 million tablets, providing strong support for the continued growth in market demand.
In terms of international collaboration, the global multicenter Phase III clinical study developed in partnership with ArriVent for furmonertinib's application in first-line treatment of NSCLC with exon 20 insertion mutations completed patient enrollment in Q1 2025. According to the latest data from the global Phase Ib randomized study FURTHER examining furmonertinib for EGFR PACC mutation NSCLC, furmonertinib 240mg achieved a median progression-free survival of 16 months as assessed by BICR, with a median follow-up period of 12.5 months and a confirmed overall response rate of 68.2%. Partner ArriVent plans to initiate an international multicenter Phase III registration clinical study for first-line treatment of PACC mutation NSCLC, with first patient enrollment expected to be completed in the second half of 2025.
In summary, during the first half of 2025, Shanghai Allist Pharmaceuticals achieved significant progress in research and development, production, and market expansion. Furmonertinib's core position continues to strengthen, the research pipeline continues to diversify, and production capacity layout advances steadily. Looking ahead, with more research achievements materializing and international market development, Shanghai Allist Pharmaceuticals is well-positioned to maintain its leading position in the non-small cell lung cancer treatment field.
Comments